Skip to main content
OpenTrials
Completed

NCT Number: NCT02728193

Standard Treatments of Very-early Stage Hepatocellular Carcinoma

The aim of our study was to elucidate the difference in the rates of complication, hospitalization days, medical expenses, MRI showed that the degree of tumor necrosis, and overall survival rates of the therapies between PEI, MVA and RFA, and make the standard for minimally invasive treatment of very early stage HCC.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Very-early Stage

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Eastern hepatobilliary surgery hospital

Shanghai, Shanghai Municipality, 200438, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Preoperative clinical, imaging and tumor markers were diagnosed as hepatocellular carcinoma
  • Tumor diameter<2cm
  • Child-Pugh class A liver function
  • Without major organ dysfunction
  • male or female patients > 18 years and <=70 years of age
  • Voluntary participation in this clinical trial

Exclusion criteria

  • Other anticancer treatment before therapy
  • Patients with apparent major organs (i.e. cardiac, pulmonary, cerebral and renal) dysfunction, which may affect the treatment of liver cancer
  • Patients with other diseases that may affect the treatment of this treatment
  • History of other malignant tumors
  • Patients who are participating in other clinical trials
  • Pregnant, lactating women

Treatment and study plan

RFA

Procedure

MWV

Procedure

Other names: Microwave ablation

PEI

Procedure

Percutaneous ethanol injection

Primary outcomes

  1. Recurrence

    Time frame: 3 years

    Hepatocellular Carcinoma will recurrence in 3 years

  2. Death

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Eastern Hepatobiliary Surgery Hospital

Other

Registry information

Official study title

The Research on Standard Treatments of Very-early Stage Hepatocellular Carcinoma: a Randomized Clinical Trial

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Apr 5, 2016
Registry last updated
Apr 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.